Literature DB >> 3267147

Imaging pattern of previously in vitro sensitized and interleukin-2 expanded autologous lymphocytes in human cancer.

B Mukherji1, O Arnbjarnarson, L A Spitznagle, R I Kalish, J Hoffman, M T Ergin, R P Spencer.   

Abstract

In vivo patterns of lymphocytes sensitized against autologous tumor (in vitro) were studied in seven patients with metastatic cancer as a potential candidate for an alternative method of radioimmunodetection and adoptive immunocytotherapy. Peripheral blood lymphocytes (PBL) were either activated in Interleukin-2 (IL-2) [lymphokine activated killer (LAK) cells] or sensitized against autologous tumor cells by in vitro co-culture (IVC) and expanded in IL-2 (educated cells); both were then labelled with 111In. Labelled autologous cells (1 x 10(7)-5 x 10(8)) were administered to patients and biodistribution studied by imaging under a gamma camera at various time intervals. In 4/7 cases, imaging with the educated cells showed concentrations of radioactivity at sites that correlated positively with clinically detectable metastatic tumor. By contrast, only one instance of positive uptake was seen with the LAK cells. Other than slight fever in three cases, infusions of labelled PBL were well tolerated. Educated lymphocytes were cytotoxic against autologous tumor cells and the cytotoxic reactivities of the educated cells were maintained in continuous culture in IL-2 for 4-6 weeks. Evidence of accumulation of radiolabelled educated autologous cells at a significantly higher frequency than that of the LAK cells suggests that in vitro expanded educated PBL might be better candidates for radioimmunodetection of human cancer, and continuous cultures of such educated autologous PBL might be sources for repeated administration of these effector cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3267147     DOI: 10.1016/0883-2897(88)90012-8

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN: 0883-2897


  4 in total

1.  Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma.

Authors:  E Schäfer; R Dummer; C Eilles; W Börner; R Martin; J Rendl; G Burg
Journal:  Eur J Nucl Med       Date:  1991

3.  [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.

Authors:  Pat Zanzonico; Guenther Koehne; Humilidad F Gallardo; Mikhail Doubrovin; Ekaterina Doubrovina; Ronald Finn; Ronald G Blasberg; Isabelle Riviere; Richard J O'Reilly; Michel Sadelain; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-11       Impact factor: 9.236

4.  Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

Authors:  E Halapi; Y Yamamoto; C Juhlin; M Jeddi-Tehrani; J Grunewald; R Andersson; C Hising; G Masucci; H Mellstedt; R Kiessling
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.